Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9160683rdf:typepubmed:Citationlld:pubmed
pubmed-article:9160683lifeskim:mentionsumls-concept:C1516476lld:lifeskim
pubmed-article:9160683lifeskim:mentionsumls-concept:C0023452lld:lifeskim
pubmed-article:9160683lifeskim:mentionsumls-concept:C0178539lld:lifeskim
pubmed-article:9160683lifeskim:mentionsumls-concept:C0029005lld:lifeskim
pubmed-article:9160683lifeskim:mentionsumls-concept:C0376515lld:lifeskim
pubmed-article:9160683lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:9160683lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:9160683lifeskim:mentionsumls-concept:C1518321lld:lifeskim
pubmed-article:9160683lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:9160683lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:9160683pubmed:issue10lld:pubmed
pubmed-article:9160683pubmed:dateCreated1997-6-19lld:pubmed
pubmed-article:9160683pubmed:abstractTextWe found a marked variation in BCL-2 oncoprotein expression levels of primary leukemic cells from 338 children with newly diagnosed acute lymphoblastic leukemia (ALL). None of the high-risk features predictive of poor treatment outcome in childhood ALL, such as older age, high white blood cell (WBC) count, organomegaly, T-lineage immunophenotype, ability of leukemic cells to cause overt leukemia in severe combined immunodeficient (SCID) mice, presence of MLL-AF4, and BCR-ABL fusion transcripts were associated with high levels of BCL-2 expression. Overall, high BCL-2 levels were not associated with slow early response, failure to achieve complete remission, or poor event-free survival. High BCL-2 levels in primary leukemic cells predicted slow early response only in T-lineage ALL patients, which comprised approximately 15% of the total patient population. Even for this small subset of patients, the level of BCL-2 expression did not have a significant impact on the short-term event-free survival.lld:pubmed
pubmed-article:9160683pubmed:languageenglld:pubmed
pubmed-article:9160683pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9160683pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9160683pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9160683pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9160683pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9160683pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9160683pubmed:statusMEDLINElld:pubmed
pubmed-article:9160683pubmed:monthMaylld:pubmed
pubmed-article:9160683pubmed:issn0006-4971lld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:SatherHHlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:NachmanJJlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:GaynonPPlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:ReamanGGlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:TubergenDDlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:AtaF AFAlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:YanoRRlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:UckunF MFMlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:SteinherzPPlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:BostromBBlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:CrottyLLlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:SarquisMMlld:pubmed
pubmed-article:9160683pubmed:authorpubmed-author:ZerenTTlld:pubmed
pubmed-article:9160683pubmed:issnTypePrintlld:pubmed
pubmed-article:9160683pubmed:day15lld:pubmed
pubmed-article:9160683pubmed:volume89lld:pubmed
pubmed-article:9160683pubmed:ownerNLMlld:pubmed
pubmed-article:9160683pubmed:authorsCompleteYlld:pubmed
pubmed-article:9160683pubmed:pagination3769-77lld:pubmed
pubmed-article:9160683pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:meshHeadingpubmed-meshheading:9160683-...lld:pubmed
pubmed-article:9160683pubmed:year1997lld:pubmed
pubmed-article:9160683pubmed:articleTitleCellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.lld:pubmed
pubmed-article:9160683pubmed:affiliationBiotherapy Institute, University of Minnesota, Roseville 55113, USA.lld:pubmed
pubmed-article:9160683pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9160683pubmed:publicationTypeMulticenter Studylld:pubmed